Targacept
09:33 :
Targacept, AstraZeneca end partnership on failed drug -
AstraZeneca PLC has formally notified Targacept Inc. that it will dissolve its collaboration and license agreement for the anti-depression drug TC-5214 that they had been working on together. That drug failed in Phase 3 clinical trials ...
09:53 :
CEO of Targacept partner AstraZeneca resigns -
The recent failure of Targacept's antidepression drug TC-5214 in clinical trials, which led the Winston-Salem company to shed half its workforce this week, may have also contributed to the downfall of the CEO of Targacept's development partner on that ...
15:59 :
McConnell: Targacept downsizing not a concern -
Dr. John McConnell, CEO of Wake Forest Baptist Medical Center, said he does not believe the downsizing at anchor tenant Targacept Inc. will have a lasting negative impact on the Piedmont Triad Research Park. Targacept ...
08:56 :
Targacept cutting its workforce in half -
Biotechnology firm Targacept Inc. will lay off 65 employees — or about 46 percent of its workforce of 142 people — following the failure of what had been its most advanced drug candidate, In an announcement, CEO Don deBethizy said the ...
12:51 :
Targacept implodes on drug failure -
BOSTON (MarketWatch) -- Shares of Targacept Inc. plunged 28% to $5.36 Tuesday after the biotech group said that a Phase III clinical trial of its antidepressant TC-5214 showed the drug was largely ineffective in treating major depressive ...
11:52 :
Targacept launching new trials for schizophrenia, ADHD drug -
Targacept will launch two new Phase 2 clinical trials of a drug known as TC-5619 as a potential treatment for both schizophrenia and attention deficit/hyperactivity disorder, according to an announcement. Earlier clinical research has ...
actualidad Targacept -